Novo Nordisk: files for approvals in US
(CercleFinance.com) - Denmark's Novo Nordisk said on Wednesday that it is seeking US approval to sell oral semaglutide for the treatment of adults with type-2 diabetes.
The submission is based on the results from clinical trials that included 9,543 adults, which showed that people treated with oral semaglutide achieved greater blood glucose reductions, the drugmaker said.
A second application has been submitted for oral semaglutide seeking approval for a cardiovascular risk reduction indication in adults with type-2 diabetes.
Finally, an application has been submitted for its once-weekly non-insulin drug Ozempic for a cardiovascular risk reduction indication in adults with type-2 diabetes.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The submission is based on the results from clinical trials that included 9,543 adults, which showed that people treated with oral semaglutide achieved greater blood glucose reductions, the drugmaker said.
A second application has been submitted for oral semaglutide seeking approval for a cardiovascular risk reduction indication in adults with type-2 diabetes.
Finally, an application has been submitted for its once-weekly non-insulin drug Ozempic for a cardiovascular risk reduction indication in adults with type-2 diabetes.
Copyright (c) 2019 CercleFinance.com. All rights reserved.